AstraZeneca PLC
AZN
$77.49
-$0.47-0.60%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 18.03% | 13.81% | 10.45% | 8.60% | 3.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.03% | 13.81% | 10.45% | 8.60% | 3.29% |
| Cost of Revenue | 19.88% | 75.06% | 42.93% | 18.82% | -6.72% |
| Gross Profit | 17.64% | 6.00% | 5.41% | 6.66% | 5.71% |
| SG&A Expenses | 7.92% | -0.97% | 3.02% | 5.39% | 3.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 81.45% | 78.54% | 75.02% | -147.87% | -183.66% |
| Total Operating Expenses | 15.90% | 18.52% | 15.61% | 8.08% | 0.49% |
| Operating Income | 25.42% | 1.74% | -3.62% | 10.39% | 14.32% |
| Income Before Tax | 25.97% | 16.84% | 28.03% | 76.69% | 175.96% |
| Income Tax Expenses | 75.91% | 62.33% | 1,202.54% | 320.44% | 218.43% |
| Earnings from Continuing Operations | 18.12% | 10.09% | 4.49% | 34.60% | 81.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 0.00% | 37.50% | 16.67% | -50.00% | -20.00% |
| Net Income | 18.14% | 10.16% | 4.51% | 34.59% | 81.17% |
| EBIT | 25.42% | 1.74% | -3.62% | 10.39% | 14.32% |
| EBITDA | 18.01% | 1.61% | -3.33% | 4.63% | 6.70% |
| EPS Basic | 18.10% | 10.14% | 4.49% | 34.53% | 81.06% |
| Normalized Basic EPS | 28.87% | 1.98% | -4.04% | 10.66% | 16.16% |
| EPS Diluted | 18.00% | 9.87% | 4.40% | 34.57% | 81.27% |
| Normalized Diluted EPS | 28.86% | 1.92% | -4.09% | 10.61% | 16.13% |
| Average Basic Shares Outstanding | 0.03% | 0.02% | 0.02% | 0.03% | 0.05% |
| Average Diluted Shares Outstanding | 0.05% | 0.06% | 0.05% | 0.05% | 0.03% |
| Dividend Per Share | 6.90% | 2.41% | 2.41% | 0.00% | 0.00% |
| Payout Ratio | -0.13% | -0.06% | -0.04% | -0.25% | -0.43% |
